• Home
  • Technology
  • Pipeline
  • Partnership
  • News
  • Career
  • Team
  • Contact

Developing the Next Generation Bispecific Antibody
Drugs to Improve Cancer Treatment



Transforming Bispecific Antibody with a New Modality



⦁ Using VHH antibodies as building blocks, we are developing novel, next-generation bispecific and multispecific antibody drugs to improve clinical outcomes for cancer patients with resistance and/or unmet medical needs.


⦁ We focus on developing novel bispecific antibody-drug conjugates and T-cell engagers to address the heterogeneity of solid tumors, the leading cause of tumor relapse when treated with monospecific tumor-associated antigen targeting therapies that only kill one subpopulation of cancer cells.



Contact


1230 Bordeaux Drive, Sunnyvale, CA 94089

Info@brightbiologicsllc.com



Copyright © 2020 Bright Biologics LLC - All Rights Reserved.